FDA
- Application: ANDA200887
- Marketing authorisation holder: TEVA PHARMS USA
- Local brand name: CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
Candesartan cilexetil / hydrochlorothiazide (Candesartan cilexetil / hydrochlorothiazide) regulatory status in United States.
Yes. FDA has authorised it.
TEVA PHARMS USA holds the US marketing authorisation.